Clinical Trial

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Name: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer — clinical trial record (NCT07294534)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.

Trial Details

NCT Number	NCT07294534
Lead Sponsor	Shanghai Henlius Biotech
Conditions	HER2 + Breast Cancer
Enrollment	817 participants
Start Date	2026-01-27
Primary Completion	2028-09-30 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-19